Prevention of recurrence of major depressive episodes In adults, the actual benefit remains substantial for ZOLOFT 50 mg and is substantial for ZOLOFT 25 mg in hard capsules.
Major depressive episodes In adults, the actual benefit remains substantial for ZOLOFT 25 and 50 mg.
Obsessive compulsive disorder (OCD) in adults as well as in paediatric patients aged 6 to 17 years In adults and children aged 6 to 17 years, the actual benefit remains substantial for ZOLOFT 25 mg and 50 mg.
Panic disorder with or without agoraphobia In adults, the actual benefit is substantial for ZOLOFT 25 and 50 mg.
Post traumatic stress disorder In adults, the actual benefit is substantial for ZOLOFT 25 and 50 mg.
Moderate
Social Anxiety Disorder In adults, the actual benefit is moderate for ZOLOFT 25 and 50 mg.
Clinical Added Value
no clinical added value
In panic disorder with or without agoraphobia, social anxiety disorder and post traumatic stress disorder, ZOLOFT does not provide any improvement in actual benefit (IAB V) compared with the other medicines available in these indications.
Listen
